Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetate in Patients with Spinal and Bulbar Muscular Atrophy (SBMA)

INTERVENTION: Leuprorelin acetate 3.75 mg subcutaneous injection every 4 weeks Placebo subcutaneous injection every 4 weeks CONDITION: Spinal and bulbar muscular atrophy (SBMA) PRIMARY OUTCOME: Motor function(ALSFRS‐R) SECONDARY OUTCOME: Frequency of aspiration pneumonia,; serum creatine kinase, serum testosterone, liver function test, HbA1c, NCV, immunohistological study of scrotal skin biopsy and Respiratory function test. INCLUSION CRITERIA: Genetically confirmed SBMA male patients in Japan who have no desire to father a child with written informed consent.